Skip to main content
Psychopharmacology Bulletin All Volumes & Issues VOL 38 Supplement No. 1 Unmet Needs in...

Unmet Needs in the Treatment of Anxiety Disorders

Psychopharmacology Bulletin 38(Suppl. 1): 31-37, 2004/03/24; https://doi.org/10.64719/pb.7086

Abstract

There are a number of unmet needs in the treatment of anxiety disorders including the need for more effective, rapidly acting, and better tolerated medications; early identification of nonresponse; effective treatments for refractory disorders; prevention of relapse; and promotion of resilience and long-lasting response. Rates of response to contemporary antidepressants and other anxiolytics are often less robust than might be hoped, and remission rates, which have until recently been infrequently measured, are even lower. A small number of mostly uncontrolled studies suggest a role for augmentation of initial therapy with a second modality in patients who do not fully remit to treatment. There also is a small but growing literature which suggests the use of novel anticonvulsants and atypical antipsychotics in the treatment of anxiety disorders should be further studied. However, a definitive place for these newer therapeutic strategies in the anxiety disorder treatment armamentarium awaits evidence from large, controlled studies.

Access This Article

Choose an access option below to view the full article.

Subscriber Access

If you or your institution has a subscription, log in to access this article.

Log In

Purchase Article

Buy single-article access with a one-time purchase.

$30.00
Add to Cart

How to Cite

Mark H. Pollack, MD. Unmet Needs in the Treatment of Anxiety Disorders. Psychopharmacology Bulletin. 2004/03/24; 38(Suppl. 1):31-37. DOI: 10.64719/pb.7086